Early halt for brain cancer combo trial
NCT ID NCT05553522
Summary
This early-stage study aimed to see if combining three cancer drugs with a precise type of radiation could better control breast cancer that had spread to the brain. It was designed for people with a specific type of breast cancer (HER2-positive) and up to 10 small brain tumors. The trial was terminated after enrolling only one person, so no results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States
Conditions
Explore the condition pages connected to this study.